Travere Therapeutics (TVTX) News Today $14.91 +0.08 (+0.54%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$14.93 +0.02 (+0.13%) As of 04/15/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Wellington Management Group LLP Makes New $583,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)Wellington Management Group LLP acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,493 shares of the company's stock, valued at apprApril 16 at 3:28 AM | marketbeat.comGuggenheim Reiterates Buy Rating for Travere Therapeutics (NASDAQ:TVTX)April 15 at 1:59 AM | americanbankingnews.com111,158 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by F M Investments LLCF M Investments LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 111,158 shares of the company's stock, valueApril 14 at 5:41 AM | marketbeat.comNorges Bank Takes $1.24 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Norges Bank bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 71,000 shares of the company's stock, valued at approximately $1,237,000. NorgeApril 14 at 3:32 AM | marketbeat.comRenaissance Technologies LLC Purchases 534,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Renaissance Technologies LLC boosted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 28.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,409,514 shares of the company's stock after purchasing an additional 534,April 13 at 5:43 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $47.00April 13 at 2:33 AM | americanbankingnews.comFederated Hermes Inc. Acquires 44,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Federated Hermes Inc. lifted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 668,315 shares of the company's stock after purchasing an additional 44,500 shares duriApril 12, 2025 | marketbeat.comScotiabank Remains a Buy on Travere Therapeutics (TVTX)April 11, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Time to Sell?Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - What's Next?April 11, 2025 | marketbeat.comVanguard Group Inc. Sells 159,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Vanguard Group Inc. lowered its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,742,165 shares of the company's stock after selling 159April 10, 2025 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from Wells FargoApril 10, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteenApril 10, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Trexquant Investment LPTrexquant Investment LP reduced its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 21.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,217 shares of the company's stoApril 7, 2025 | marketbeat.comSchroder Investment Management Group Sells 260,199 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Schroder Investment Management Group trimmed its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 38.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 417,253 shares of the company's stock after selling 260,199 shares during theApril 6, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Travere Therapeutics (NASDAQ:TVTX)Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research report on Thursday.April 5, 2025 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from GuggenheimApril 5, 2025 | markets.businessinsider.comNovartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedApril 3, 2025 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Lessened by Pictet Asset Management Holding SAPictet Asset Management Holding SA trimmed its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 709,390 shares of the company's stock after selling 53,518 sharesApril 3, 2025 | marketbeat.comThe Analyst Verdict: Travere Therapeutics In The Eyes Of 7 ExpertsApril 3, 2025 | benzinga.comBank of America Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $31.00Bank of America lifted their price objective on shares of Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Tuesday.April 2, 2025 | marketbeat.comKnott David M Jr Has $3.97 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Knott David M Jr decreased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 228,000 shares of the company's stock after sellApril 2, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Down 8% - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Shares Down 8% - Should You Sell?April 1, 2025 | marketbeat.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025March 31, 2025 | finance.yahoo.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025March 31, 2025 | businesswire.comTwo S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market StrugglesMarch 29, 2025 | investors.comPrudential Financial Inc. Acquires 365,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Prudential Financial Inc. lifted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 60.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 969,141 shares of the company's stock after purchasMarch 29, 2025 | marketbeat.comEntryPoint Capital LLC Acquires New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)EntryPoint Capital LLC bought a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,600 shares of the company's stock, valuedMarch 28, 2025 | marketbeat.comSwiss National Bank Has $2.65 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Swiss National Bank lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 151,900 shares of the company's stock after purchasing an additional 17,20March 28, 2025 | marketbeat.comIs Market Volatility Good For Small-Cap Stocks?March 27, 2025 | uk.finance.yahoo.comIs Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode?March 27, 2025 | msn.comFox Run Management L.L.C. Purchases Shares of 25,708 Travere Therapeutics, Inc. (NASDAQ:TVTX)Fox Run Management L.L.C. purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,708 shares of the company's stock, valued at approximately $448,000. A number of other insMarch 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Emerald Advisers LLC raised its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,125,744 sharesMarch 24, 2025 | marketbeat.comSemanteon Capital Management LP Acquires 48,084 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Semanteon Capital Management LP lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 131.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 84,783 shares of the company's stocMarch 22, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 661,603 shares of the company's stock after buying an additioMarch 22, 2025 | marketbeat.comTravere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGSMarch 17, 2025 | finanznachrichten.deTravere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGSMarch 17, 2025 | markets.businessinsider.comTravere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGSMarch 17, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Has $7.43 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Connor Clark & Lunn Investment Management Ltd. cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 426,726 shares of the company's stock after selling 98March 16, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have assignMarch 15, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Up 6.7% - Time to Buy?Travere Therapeutics (NASDAQ:TVTX) Shares Up 6.7% - What's Next?March 13, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 12, 2025 | globenewswire.comUS Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)US Bancorp DE increased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 323.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,795 shares of the company's stock after acqMarch 12, 2025 | marketbeat.comTravere Therapeutics: Tricky Outlook Gives Me Pause For Thought - DowngradeMarch 7, 2025 | seekingalpha.comIeq Capital LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)Ieq Capital LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 20,749 shares of the company's stock, valued at approximately $361,000. OtherFebruary 28, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for TVTXTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will post earninFebruary 27, 2025 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockJPMorgan Chase & Co. upped their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday.February 26, 2025 | marketbeat.comWedbush Predicts Lower Earnings for Travere TherapeuticsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Wedbush lowered their Q4 2025 earnings per share estimates for shares of Travere Therapeutics in a research report issued on Monday, February 24th. Wedbush analyst L. Chico now forecasts that the company will earn $0.12 per share for the quFebruary 26, 2025 | marketbeat.comImpax Asset Management Group plc Takes $5.23 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Impax Asset Management Group plc purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 300,000 shares of the company's stock, valued at approximately $5,226,000. ImpaxFebruary 25, 2025 | marketbeat.comTravere Therapeutics to Participate at Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comCitigroup Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00Citigroup lifted their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday.February 24, 2025 | marketbeat.com Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.910.79▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼156▲TVTX Articles Average Week Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Axsome Therapeutics News Today Nuvalent News Today ADMA Biologics News Today Krystal Biotech News Today Grifols News Today Cytokinetics News Today Verona Pharma News Today Elanco Animal Health News Today Vaxcyte News Today Rhythm Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts